Novogen Limited (NASDAQ:KZIA) Short Interest Update

Novogen Limited (NASDAQ:KZIA) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 45,079 shares, a decline of 33.9% from the February 26th total of 68,201 shares. Approximately 2.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 144,252 shares, the days-to-cover ratio is currently 0.3 days.

Novogen Stock Down 1.4%

NASDAQ:KZIA traded down $0.10 during mid-day trading on Friday, hitting $7.16. 177,897 shares of the company’s stock were exchanged, compared to its average volume of 123,474. Novogen has a fifty-two week low of $2.86 and a fifty-two week high of $17.40. The company has a 50 day simple moving average of $7.02 and a 200-day simple moving average of $7.75.

Novogen (NASDAQ:KZIA) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($1.34) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

A number of research analysts have recently commented on KZIA shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Novogen in a research note on Wednesday, January 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Novogen from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $19.00.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.